Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 9NETWORK 1INDUSTRY 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 538Gynecologic 158Breast 99Other solid neoplasm 56Head & Neck 51Tumor-Agnostic 45Gastrointestinal 40Genitourinary 37Dermatologic 17CNS 16Lymphoid 13Sarcoma 9Endocrine 8Other hematologic neoplasm 2NET 2Classical hematology 1

Conditions

Thrombocytopenia 1Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Epoetin Alfa 38Darbepoetin alfa 30epoetin beta 10Rivaroxaban 9olaparib 5eltrombopag 5apixaban 5Heparin, Low-Molecular-Weight 5pegylated granulocyte colony-stimulating factor 4pegfilgrastim 4emicizumab 4Gemcitabine 4Filgrastim 4Dalteparin 4Cyclophosphamide 4AP 1903 reagent 4romiplostim 3peginesatide 3luspatercept 3hetrombopag 3hematide 3Vancomycin 3ON 01910 3Enoxaparin 3Azacitidine 3ACE-011 3venetoclax 2telapristone acetate 2roxadustat 2iron isomaltoside 1000 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carboplatin × Classical hematology × Clear all
NCT00413283 2013-10-24

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Amgen

Phase 2 Completed
63 enrolled 15 charts
Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡